NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

What happened

NeuroSense plans to add newly generated neurofilament light chain (NfL) analysis to its proposed New Drug Submission for PrimeC, an investigational ALS treatment, in Canada. The company now targets a March 2027 filing, later than its previous December 2026 timetable; Health Canada has no concerns with the revised timing.

Proposed

Global impact / market context

Adding NfL analysis could give regulators more evidence to assess PrimeC, but it does not establish that the treatment works or will be approved. The later filing target also delays the next regulatory step, while any eventual Canadian marketing opportunity remains conditional on review and approval.

Analyst inference

This would be NeuroSense’s first marketing application in any jurisdiction, so the Canadian review could be an important step toward potential commercialization. The article says the submission could address about 4,000 Canadians living with ALS, but gives no sales forecast or approval outcome.

Analyst inference

What to watch

1. Whether NeuroSense files the proposed submission by March 2027, including the added NfL analysis and other planned evidence, will indicate if the revised timetable holds. Analyst inference
2. Health Canada’s review and any decision on PrimeC will determine whether the investigational therapy can be marketed in Canada; the article reports no approval yet. Analyst inference
3. The article says the expanded package will include Phase 2b PARADIGM results published in JAMA Neurology; assess how regulators weigh those results alongside the new NfL analysis. Confirmed

Evidence

• Original source link unavailable